

THE VIEW

Life sciences | February 2021



Hi there,

2021 has seen the beginning of COVID-19 vaccine deployments, with clinical trials continuing to test and improve efficacy rates. Meanwhile, digital technologies are disrupting the life sciences industry, changing the face of R&D processes. In this month's newsletter, we take a look at major developments in the pharma sector, including the status of COVID-19 vaccines, along with the latest IPOs and funding trends.



7 Pharma trends to watch for in 2021

The COVID-19 pandemic has put a spotlight on the pharma sector, upturning traditional and new industry platforms and practices. As pharma companies continue to respond to challenges, here are the major trends in the industry that will dominate the future >>



Digital health funding and M&A trends

During COVID-19, digital health has turned healthcare into a more open, data-first market, gaining record funding of over USD 20B in 2020. Here's a look at its key funding and M&A trends. >>




The rise of digital behavioral health

Digital behavioral health companies raked in USD 1.6B funding in 2020, the highest ever reported. Let's look at the top funding deals and trends in this field. >>

Top 10 life sciences IPOs so far in 2021

This year, the life sciences sector has witnessed a roaring start in terms of IPOs. Here's a list of the top ten IPOs that have been offered in 2021 till date.



COVID-19 developments

With the increasing push to inoculate people against COVID-19, all eyes are on vaccine manufacturers and their candidates. With various pharmas aiming to roll out of vaccines this year, here's a look at where they currently stand in the pipeline.


Developers	Country of origin	Name of Vaccine	Phase	Current Status	Efficacy Rate
1 Pfizer-BioNTech	USA, Germany	BNT162B2	2,3	Approved in several countries. Emergency use in U.S., E.U., other countries.	95%
2 Moderna	USA	mRNA-1273	3	Approved in Switzerland. Emergency use in U.S., U.K., E.U., others.	94.10%
3 Gamaleya	Russia	Sputnik V	3	Early use in Russia. Emergency use in other countries.	91.40%
4 Oxford-AstraZeneca	UK, Sweden	Covishield	2, 3	Emergency use in U.K., E.U., other countries.	70.40%
5 Sinovac	China	CoronaVac	3	Approved in China. Emergency use in Brazil, other countries.	50.40%
6 CanSino	China	Convidicea	3	Limited use in China.	65.70%
7 Bharat Biotech	India	Covaxin	3	Emergency use in India.	NA
8 Sinopharm	China	BBIBP-CorV	3	Approved in China, U.A.E., Bahrain. Emergency use in Egypt, other countries.	79%
9 Johnson & Johnson	USA, Belgium	JNJ-78436735	3	Phase 3 clinical trial	66%
10 Novavax	USA	NVX-CoV2373	3	Phase 3 clinical trial	89.30%

Risks and challenges in the global COVID-19 vaccine deployment. (Mckinsey)

Possible mutations in the COVID-19 virus and its effect on the vaccines. (BBC)

COVID-19 accelerated innovation in therapy and clinical trials. (express pharma)

Netscribes helps life sciences firms build a competitive advantage through actionable data and insights. To schedule a consultation, [contact us](#)



41 East, 11th Street, New York
NY10003, USA
+1-877-777-6569
info@netscribes.com



Subscribe to our newsletter

This email was sent to {{ contact.EMAIL }}
You received this email because you are registered with Netscribes

[Unsubscribe here](#)

© 2020 Netscribes